Breaking AI & Tech News Analyzed

The Lead Doctors, scientists, and researchers shared new research about ways to tackle cancer at the 2026 American Society of Clinical Oncology (Asco) annual meeting, the world's largest cancer conference. Breakthroughs in Cancer Treatment The event in Chicago, attended by 40,000 health professionals, featured more than 200 sessions and 2,700 poster presentations on this year's theme, “the science and practice of translation: improving cancer outcomes worldwide”. Smart Drugs in Cancer Treatment Researchers have developed a smart drug that stops cancer cells hiding. The experimental tablet, GRWD5769, can help shrink tumours by at least 30% in six of the world’s most common forms of the disease, delegates in Chicago were told. 26 of 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers who were given GRWD5769 alongside cemiplimab had tumour reductions of at least 30%. 15 had tumour reductions of at least 30%. A Daily Pill for Pancreatic Cancer A pill that doubles survival time in patients with pancreatic cancer was presented at the conference. In a trial of 500 patients, all of whom had pancreatic cancer that had spread, the pill, daraxonrasib, doubled survival time, with fewer side-effects compared with chemotherapy. Patients who took the drug lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy. Safely Skipping Some Treatments Some patients can safely skip some treatments, according to research presented at the conference. A genomic test could pave the way for a new era of personalised medicine, enabling doctors to determine which patients can safely skip chemotherapy. The Optima trial, led by University College London, followed 4,000 patients with newly diagnosed breast cancer in the UK, Norway, Sweden, Australia, New Zealand and Thailand. Those with a low score on the genomic test could be treated safely with hormone therapy alone. The Future of Cancer Treatment Urgent action is required to cope with rising cancer cases. The world faces a cancer workforce crisis, experts said, with a shortage of 100 million staff expected by 2050 when 100,000 people will be being diagnosed every day. A 21% increase in cancer incidence is predicted, according to a report presented at the conference. The rate is set to rise from 165 per 100,000 people in 2025 to 200 per 100,000 in 2050.

The Lead Cancer, a leading cause of death worldwide, is a complex and multifaceted disease. Recent advances in treatment, including a new drug called daraxonrasib for pancreatic cancer, offer hope, but challenges persist. The Event Details Daraxonrasib, a daily pill, has shown promise in doubling the survival time of patients with pancreatic cancer in a 500-person trial. This drug works by targeting a protein called Kras that causes cancer cells to grow and divide. Additionally, a new vaccine, amivantamab, for head and neck cancer has demonstrated effectiveness in shrinking tumors in over a third of patients in a 102-person trial. The Data Analysis Globally, cancer causes nearly one in six deaths, with 10 million deaths annually. While survival rates for some cancers, like melanoma and prostate cancer, exceed 90% in many rich countries, others, such as pancreatic cancer, remain difficult to treat. In the UK, only about one in 20 people with pancreatic cancer survives five years after diagnosis. The Impact Analysis The fight against cancer is hindered by a significant shortage of medical staff. Research estimates a global shortfall of 100 million cancer care workers by 2050, including 65 million nurses and 16 million diagnostic staff. Early diagnosis and rapid treatment are critical, but currently, one in three cancer cases worldwide are undiagnosed, and many cancers are diagnosed at a late stage. The Prediction Despite the challenges, advances in precision medicine and targeted treatments offer a promising future for cancer treatment. As research continues to uncover the complexities of cancer, it is likely that treatment approaches will become increasingly tailored to specific types of cancer and patient populations. However, addressing the global shortage of cancer care workers and improving early diagnosis and treatment are crucial to making progress against this disease.

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."